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Kidney stones probably grow during crystalluria by crystal sedimentation and aggregation (AGN) on stone surfaces. This process
has to occur within urinary transit time (UT) through the kidney before crystals are washed out by diuresis. To get more
information, we studied by spectrophotometry the formation and AGN of Ca oxalate (Ca Ox) crystals which were directly
produced in urine of 30 stone patients and 30 controls by an oxalate (Ox) titration. Some tests were also performed after removing
urinary macromolecules (UMs) by ultraﬁltration. To induce rapid crystallization, high Ox additions (0.5–0.8mM) were necessary.
The most important ﬁnding was retardation of crystal AGN by UM. In urine of 63% of controls but only 33% of patients, no AGN
was observed during an observation of 60 minutes (P<0.05). Also growth and sedimentation rate of crystals were signiﬁcantly
reduced by UM. For stone metaphylaxis, especially for posttreatment residuals, avoiding dietary Ox excesses to prevent crystal
formation in the kidney and increasing diuresis to wash out crystals before they aggregate are recommended.
1.Introduction
After minimal invasive treatment, stone residuals are found
in 20–25% of patients [1, 2]. These stone fragments are
an interesting model to study stone growth in vivo.D e -
pending on observation time, 20–37% of stone residuals
show further growth which can lead to complications and
secondary interventions [2, 3]. On the other hand, in a
retrospective study, the size of isolated and not infected stone
residuals after extracorporeal shock wave lithotripsy (ESWL)
remained stable in 24 of 83 patients even during an average
observation time of 3.5 years [3]. These observations suggest
that stone formation occurs only periodically. Therefore,
questions arise about factors inducing stone growth and
about rational measures of prevention.
Scanning microscopy of kidney stones shows within an
organic matrix a highly aggregated crystal structure [4].
Already in 1969, it was demonstrated that stone patients
have a tendency to excrete large crystal aggregates [5]. In the
meantime, many indices were found that crystal aggregation
(AGN) is an important process in stone formation [6]a n d
e s p e c i a l l yi ns t o n eg r o w t h[ 7]. In urine, crystals are always
coated by a layer of urinary proteins [8], which essentially
inﬂuence crystallization processes. Main urinary proteins
thoughttobeinvolvedinstoneformationarealbumin,inter-
alpha-inhibitor, nephrocalcin, osteopontin, prothrombin
fragment 1, and Tamm Horsfall protein or uromodulin. Gly-
cosaminoglycans seem to be of minor importance [9]. Much
work was done to evaluate the inﬂuence of these substances
on crystallization processes especially of Ca oxalate (Ca Ox),
thepredominantstonemineral[9,10].However,resultswere
controversial, and the impact on stone prevention remained
minimal[10].Thethreecrystallizationprocesses,nucleation,
crystal growth, and AGN, often were separately examined in
diﬀerent test systems [11, 12]. Tests were often performed
in artiﬁcial solutions with the addition of urine in high
dilution or of previously isolated urinary proteins [6, 13].
AGN generally was studied using preformed crystals. These
crystals were, for reasons of reproducibility, produced in
protein-free solutions and ripened for several hours or days
[14, 15]. However, AGN being relevant for stone formation
bases on freshly precipitated crystals which are coated by
urinaryproteinsandwhichaggregatewithintheshorttransit
time of crystals through the kidney and the urinary tract2 Advances in Urology
[16,17].Therefore,wetriedtostudytheformationandAGN
of Ca Ox crystals which we directly produced in urine by
an Ox titration. Crystallization was continuously observed
by spectrophotometry, and some sediments were analyzed
by scanning electron microscopy [17, 18]. Recently, these
crystallizationtestswereperformedinurineofstonepatients
and controls to get more information about general aspects
of crystal AGN [19]. In this paper, results of the mentioned
study were evaluated especially with respect to stone growth
and were completed by repeating some tests after removing
urinary macromolecules by ultraﬁltration.
2.MaterialandMethods
2.1. Collection of Urine and Preparation of Urine and Control
Solution. Urine was collected from 30 patients (24 men and
6 women aged 16–79, mean 52 years) prior to undergoing
ESWL for a calcium stone and therefore being under similar
conditions like patients with stone residuals after minimal
invasive treatment. Urine of controls was collected from 30
patients without a history of urological or nephrological dis-
ease (22 men and 8 women aged 16–80, mean 52 years) prior
to undergoing hand surgery. Patients and controls being
on free diet were fasting at least two hours before starting
the urinary collection period, which exactly was recorded.
Urine volume was determined, and urine with a pathology
on stick examination (Combur Test UX, Roche, Switzerland)
was excluded with the exception of microhematuria which is
frequent in patients with a stone in situ and therefore also
representative for the situation of stone growth.
To obtain comparable results, our intention was to per-
form crystallization tests at almost identical states of super-
saturation. Therefore, from the collection period, a volume
corresponding to a diuresis of 100mL/h was calculated, and
all urines were diluted with distilled water to a volume
corresponding to this diuresis. This dilution allowed to
equalize diﬀerences of urine composition due to diﬀerent
statesofdiuresisandtoadaptallsamplestothesameionicCa
and sodium concentration before performing crystallization
tests. Also endogenous urinary oxalate concentration was
minimized being after dilution 0.13 ± 0.05mM in patients
and 0.08 ± 0.03mM in controls. A control solution was
prepared by buﬀering distilled water with 5mM sodium
cacodylate.
2.2. Crystallization Study. pH was adjusted in all samples
to 6.0. In urine, Ca and sodium concentrations were deter-
mined by an ion-selective electrode (AVL List GmbH, Graz,
Austria). In urine and in control solution (CS), ionic Ca
was adjusted to 2.0mM and sodium to 100mM. 2mL of
urine, and CS were placed in a quartz micro cuvette within
a thermostat-table cell holder of a Perkin Elmer spectropho-
tometer 550S (Perkin Elmer, Rotkreuz, Switzerland) at 37◦C.
Under continuous stirring, Ox concentration was raised by
0.1mM sodium oxalate per minute up to a ﬁnal addition
of 1.5mM. High Ox concentrations were used because in
a previous study after addition of 1.0mM Ox to urine of
healthycontrolsnoAGNwasfound[17].UrinaryOxwasnot
taken into account since it was even in 90% of stone patients
less than 10% of the Ox addition.
During and after oxalate titration, optical density
(OD)—reﬂecting the concentration of particles being sus-
pended in urine and control solution—was monitored by
the spectrophotometer at 620nm wavelength. From the time
where an increase of OD was observed and from titration
rate, the critical Ox addition necessary to induce crystal
formation, called metastable limit, was calculated. At the end
of Ox titration, maximal OD (mOD) was measured, and
stirring was stopped. The decrease of OD (dOD/dt, min−1)
reﬂecting crystal sedimentation and AGN was followed
during a further observation time of 60 minutes. From mOD
and initial dOD/dt, a sedimentation rate (SR, mm/min) was
calculated by the following equation where L represents the
height of the light beam (7mm) in the spectrophotometer:
SR =
L ×(dOD/dt)
mOD
(1)
crystallizationtestswererepeatedafterultraﬁltrationofurine
of 10 healthy controls in a hemodialyser (Hemoﬂow F3,
Fresenius AG, Bad Homburg, Germany), the exclusion limit
of the dialysis membrane being 5kD.
2.3. Statistics. Probabilities were calculated by Mann-Whit-
ney U test and by Fisher’s test.
3. Results
Figure 1 shows a typical spectrophotometric crystallization
curve which can be separated into a titration and a sedimen-
tation phase. After 6min of Ox titration corresponding to
an addition of 0.6mM sodium oxalate, optical density (OD)
started to increase (Pt. 1). From this critical Ox addition
called metastable limit (ML) and the initial urinary Ox
concentration in the test system, the critical supersaturation
being necessary to induce crystal nucleation can be calcu-
lated. Pt. 2 marks the maximal OD or crystal concentration,
respectively, reached by the Ox titration. After the end of
the titration where stirring was stopped, a phase of slow
OD decrease started almost immediately (Figure 1,P t .2 -
3). In previous studies, this slow OD decrease could be
attributed by scanning electron microscopy (SEM) of the
corresponding sediments to the sedimentation of single
crystals of Ca Ox monohydrate [17, 18]. After a certain
time (Pt. 3) called suspension stability (SS), a rapid decrease
of OD was observed, which indicates AGN since sediments
obtained after such rapid OD decreases showed large crystal
aggregates in high concentration [17, 18].
In Figure 2,metastablelimit(ML),maximalOD(mOD),
and suspension stability (SS) observed in urine of stone
patients (UP), in urine of healthy controls (UC), and in
control solutions (CS) were compared. Mean values of ML
were signiﬁcantly higher in UP and UC than in CS (P<
0.01) demonstrating that in UP and UC due to inhibition
of crystal nucleation despite the presence of urinary Ox,
more Ox addition was necessary to induce crystallization.
Also mOD reﬂecting crystal concentration after titrationAdvances in Urology 3
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Figure 1: Spectrophotometric crystallization curve: (1) start of
increase of optical density (OD) reﬂecting crystal concentration
in urine, (2) maximal OD (mOD) reached at the end of oxalate
titration, (2)-(3) slow OD decrease (dOD/dtS) by sedimentation of
single crystals, and (3) start of rapid OD decrease (dOD/dtR) indi-
cating crystal aggregation.
was in UP and UC signiﬁcantly higher than in CS (P <
0.001). Since initial supersaturation and crystal deposit (on
average 1.35mM) were almost identical in all experiments,
an increased mOD means that in UP and UC under identical
conditions more and smaller crystals were produced than
in CS. This eﬀect can only be explained by an inhibition of
crystal growth. However, the most interesting ﬁnding was
made with respect to suspension stability (SS). A group of
UP as well as of UC showed compared to CS a signiﬁcantly
higher SS or retardation of AGN, respectively (P < 0.001).
I nas e c o n dg r o u po fU Pa n dU Ce v e na f t e ra no b s e r v a t i o n
time of 60min, no signs of AGN were found. Interestingly,
this absence of AGN was more frequent in urine of healthy
controls than of stone patients (63% versus 33%, P < 0.05).
To get more information about the source of urinary
inhibition of nucleation, growth, and AGN, we compared
metastablelimit(ML),maximalOD(mOD),andsuspension
stability (SS) observed in urine of 10 controls before and
afterultraﬁltrationofurinebyamembranewithanexclusion
limit of 5kD. Results of urine of controls (UCs) containing
urinary macromolecules >5kD (UM) and ultraﬁltrate (UF)
containing only low-molecular-weight compounds were
compared with results obtained in the control solution (CS).
Figure 3 shows that inhibition of crystal nucleation can
be attributed to low-molecular-weight compounds of urine
since no signiﬁcant diﬀerence was found with respect to ML
between UC and UF. On the other hand, elevated values
of mOD indicating inhibition of crystal growth and of SS
representing retardation of AGN were exclusively found in
UC and therefore seems to be caused by UM.
For stone growth, crystals have to accumulate on stone
surfaces which in vivo mainly seems to occur by sedimenta-
tion [18]. Therefore, we calculated the sedimentation rate of
singlecrystals(SR)inUC,UF,andCSfromslowdOD/dtand
mOD using (1). In Figure 4,m e a nv a l u e s± SD of dOD/dtS,
mOD, and SR are listed. UC showed compared to UF and
CS a signiﬁcantly lower SR (P<0.01). Since dOD/dtS values
were nearly identical in the three groups, the low SR of UC
could exclusively be attributed to the signiﬁcantly elevated
mOD (P<0.001) which, as explicated above, indicates a
decreased crystal size. This ﬁnding is in agreement with the
rule of stoke that sedimentation rate increases as a function
of particle diameter in square and conﬁrms that UM mainly
seems to be responsible for the inhibition of crystal growth.
4. Discussion
Retardation of crystal aggregation (AGN) by urinary macro-
molecules (UMs) was the most important ﬁnding when
studying Ca Ox crystallization directly in urine. Although
crystallization was induced by high Ox concentrations, urine
of 63% controls but only of 33% stone patients showed no
signs of AGN during an observation time of 60 minutes. In
theremainingurines,AGNoccurredwithanaveragedelayof
20 minutes. For stone growth, AGN between crystals being
suspended in urine and kidney stones has to occur within
urinary transit time (UT) through the renal pelvis, before
crystals are washed out by diuresis. Therefore, retardation
of AGN seems to be a natural mechanism to prevent stone
growth. Average UT in renal pelvis being reciprocal to
diuresis was calculated dividing average volume of renal
pelvis of 7mL by an average diuresis of 0.6mL/min and
found to be in the range of 12 minutes [16]. Retardation
of AGN by UM together with other factors discussed
below may explain why stone formation is limited to about
10% of the population and has a recurrence rate of only
0.10–0.15 stones/patient and year [20], although urinary
supersaturation especially with respect to Ca oxalate and
crystalluria is common.
Rational stone metaphylaxis should either intend to
prolongtheretardationofAGNortoreduceUTinorderthat
crystals are washed out before they can aggregate with stones
or stone fragments. Retardation of AGN seems to base on
urinary macromolecules (UMs) which coat urinary crystals
[8]. These UM coats separate crystals in a distance where
Van der Waal’s forces, generally thought to be responsible
for AGN, become extremely week [21]. Other mechanisms
of AGN are therefore discussed. AGN in urine could base on
viscous binding by pathological UM [13] or on Ca bridges
between electronegative UM coats of the crystals [22]. UM
cannot therapeutically, with the exception of rare cases of
pathological Tamm Horsfall protein [23], be inﬂuenced
until now. Experiments to prolong the delay of AGN by
the addition of high doses of citrate or pyrophosphate to
UM have failed [19]. However, UT in the renal pelvis, as
the calculation above shows, can eﬃciently be reduced by
an increase of diuresis or of ﬂuid intake, respectively. The
fear that increased diuresis by dilution of crystallization
inhibitors has a negative eﬀect on crystallization conditions
seems not to be justiﬁed [24]. Also in our study, a high
inhibition of crystal growth and AGN was found despite of
urine dilution corresponding to a diuresis of 100mL/hour.
Crystalaccumulationonstonesurfacesisanotherimpor-
tant factor for stone growth during crystalluria. Studies of
crystal diﬀusion and sedimentation revealed that in vivo4 Advances in Urology
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Figure 2: Crystallization parameters in urine of stone patients (UPs) and of controls (UCs) and in control solution (shaded area, mean ±
SD): ML (metastable limit = Ox addition necessary to induce crystallization), mOD (maximal optical density reached at the end of Ox
titration), and SS (suspension stability = time after titration without aggregation).
sedimentation seems to be the most eﬃcient mechanism
for crystal accumulation on stone surfaces [18]. Crystal
accumulation on stone surfaces (mmol/cm2 and min) can be
calculated multiplying crystal concentration (mmol/cm3)b y
sedimentation rate of crystals (cm/min). In urine, due to the
inhibition of crystal growth by UM, relative low sedimenta-
tion rates were found, which like SS therapeutically can not
be inﬂuenced until now. Reducing urinary supersaturation
with respect to stone minerals together with an increase
of diuresis which also reduces supersaturation remains
therefore the base of every rational stone metaphylaxis.
These measures can also prevent crystal formation in the
kidney which occurs in distal segments of the nephron
w h e r eU Ti si nt h eo r d e ro f1 – 1 . 5m i n u t e s[ 25, 26]. In our
experiments, Ox additions of 0.5–0.8mM were necessary
to induce rapid crystal nucleation. In nonhyperoxaluric
patients, such high Ox concentrations are only observed in
urine after excessive ingestion of Ox-rich food [27]. Dietary
excesses with chocolate, ice tea, and other products with
a high Ox content should therefore strictly be avoided.
In a recent study, medical treatment by alkaline citrate
was found to signiﬁcantly reduce the formation of new
stones and the growth of stone residuals after ESWL or
percutaneous nephrolithotomy. However, the incidence of
patients with hypocitraturia was with 43% extremely high
in this study [28]. Citrate is an excellent chelator of Ca
which can reduce ionic Ca concentration below the value of
1.2mM found to be essential for AGN [29] but otherwise
at least in our experiments had no direct inﬂuence on
crystallization conditions [19]. In another study performed
in 100 patients with stone residuals after ESWL, thiazide
reduced the incidence of a secondary intervention from
42% to 18% [30]. However, it is not clear whether this
beneﬁcial eﬀect can be attributed to a stabilization of stone
growthbyreducingurinaryCaconcentrationormainlytoan
acceleratedelimination ofstone fragmentsdue toan increase
of diuresis.
5. Conclusions
There is evidence that kidney stones grow by crystal AGN on
stone surfaces during crystalluria. To aggregate, crystals have
to settle to the stone surfaces by sedimentation. Sedimenta-
tion rate increases with increasing particle size. Therefore,
urinary macromolecules (UMs) inhibiting crystal growth
and decreasing sedimentation rates are an important factor
preventing stone growth. Another even more important
factor is the ability of UM to retard AGN until crystals,
being suspended in urine, are washed out of the kidney by
diuresis. Rational prevention of stone growth therefore tendsAdvances in Urology 5
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Figure 3: Crystallization parameters (see Figure 2) in urine of controls (UCs), in ultraﬁltrate of the same urine (UF), and in control solution
(shaded area).
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Figure 4: Slow OD decrease (dOD/dtS), maximal optical density (mOD), and sedimentation rate of single crystals (SRs) in urine of controls
(UCs), in ultraﬁltrate of the same urine (UF), and in control solution (CS), mean ± SD.6 Advances in Urology
to increase diuresis and to avoid excessive oxalate intake
which can provoke crystal formation already in the kidney.
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